Search

NasoVAX

As of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230). … The compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a nearly 6-fold cellular immune response in comparison to an injectable vaccine[L16313].

ARQ 171

Tixocortol

Tixocortol is a 21-thiol derivative of hydrocortisone classified as a class A corticosteroid. It is a synthetic steroid with topical anti-inflammatory properties without the systemic glucocorticoid and mineralocorticoid activities and to...

PGX-100

PGX-100 is an intravenous dosage form of modified heparin.

Managlinat dialanetil

CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.

XC221

XC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.

Iodine povacrylex

Iodine povacrylex (DuraPrep) is a surgical solution, film-forming iodophor complex that provides fast acting, persistent, broad-spectrum antimicrobial activity. DuraPrep solution is indicated for use as a patient preoperative skin prepar...

Procaterol

A long-acting beta-2-adrenergic receptor agonist. It is a potent bronchodilator that may be administered orally or by aerosol inhalation.

IDM-4

IDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia.

Abarelix

Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.